2. Protein Tyrosine Kinase/RTK
    Stem Cell/Wnt
    JAK/STAT Signaling
    Epigenetics
    Autophagy
    Apoptosis
  3. FLT3
    JAK
    RET
    Autophagy
    Apoptosis
  4. TG101209

TG101209 

Cat. No.: HY-10410 Purity: 99.22%
COA Handling Instructions

TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

For research use only. We do not sell to patients.

TG101209 Chemical Structure

TG101209 Chemical Structure

CAS No. : 936091-14-4

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 86 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 86 In-stock
Estimated Time of Arrival: December 31
Solid
5 mg USD 77 In-stock
Estimated Time of Arrival: December 31
10 mg USD 110 In-stock
Estimated Time of Arrival: December 31
50 mg USD 165 In-stock
Estimated Time of Arrival: December 31
100 mg USD 275 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 4 publication(s) in Google Scholar

Top Publications Citing Use of Products

View All JAK Isoform Specific Products:

View All Isoforms
JAK1 JAK2 JAK3 Tyk2 JAK

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

IC50 & Target[1]

JAK2

6 nM (IC50)

JAK3

169 nM (IC50)

RET

17 nM (IC50)

FLT3

25 nM (IC50)

In Vitro

TG101209 is an orally bioavailable, small molecule, ATP-competitive inhibitor towards several tyrosine kinases. TG101209 inhibits growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with an IC50 of 200 nM. In a human JAK2V617F-expressing acute myeloid leukemia cell line, TG101209 induces cell cycle arrest and apoptosis, and inhibits phosphorylation of JAK2V617F, STAT5 and STAT3. TG101209 suppresses growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations[1]. TG101209 significantly reduces STAT5 phosphorylation without affecting the total amount of STAT5 protein[2]. TG101209 inhibits survivin and reduces phosphorylation of STAT3 in HCC2429 and H460 lung cancer cells. TG101209 results in radio sensitization of HCC2429 and H460 lung cancer cells in vitro[3]. A recent study indicates TG101209 abrogates BCR-JAK2 and STAT5 phosphorylation, decreases Bcl-xL expression and triggers apoptosis of transformed Ba/F3 cells[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo

TG101209 (100 mg/kg) effectively prolongs the survival in JAK2V617F-induced disease (10 days). Compared with placebo-treated animals, TG101209-treated animals exhibit statistically significant, dose-dependent reduction in the circulating tumor cell burden at day +11 to 20%[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

509.67

Appearance

Solid

Formula

C26H35N7O2S
CAS No.
SMILES

O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)N4CCN(CC4)C)=NC=C2C)=C1)(NC(C)(C)C)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 50 mg/mL (98.10 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9621 mL 9.8103 mL 19.6205 mL
5 mM 0.3924 mL 1.9621 mL 3.9241 mL
10 mM 0.1962 mL 0.9810 mL 1.9621 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.75 mg/mL (5.40 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.75 mg/mL (5.40 mM); Clear solution

*All of the co-solvents are available by MCE.
Purity & Documentation

Purity: 99.22%

COA (245 KB) LCMS (267 KB)

Handling Instructions (2659 KB)
References
Cell Assay
[1]

In brief, approximately 2×103 cells are plated into microtiterplate wells in 100 mL RPMI-1640 growth media with indicated concentrations of TG101209. The relative growth of cells is quantified at 24-hour intervals using Cell Proliferation Kit II (XTT) as per manufacturer's guidelines. After incubation, 20 mL of XTT is added to the wells and allowed to incubate for 4-6 hours. The colored formazan product is measured spectrophotometrically at 450 nm with correction at 650 nm, and IC50 values are determined using the GraphPad Prism 4.0 software. Data are subjected to a non-linear regression-fit analysis and IC50 values are determined as the concentration that inhibits proliferation by 50%. All experiments are done in triplicate and the results normalized to growth of untreated cells.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1]

Severe combined immunodeficiency (SCID) mice are intravenously injected with 10 times 106 sorted GFP-positive BaF/3 cells expressing JAK2V617F (Ba/F3-V617F-GFP). TG101209 is administered by oral gavage at the indicated doses beginning day +3 after tumor cell infusion and ending on day +20. On day +11 following tumor cell injection, 1 mL blood is collected by terminal cardiac bleeding from the mouse that receives vehicle, and 0.1 mL of blood is collected by non-lethal retro-orbital collection from each of the three six-mouse groups dosed with 10, 30 or 100 mg/kg b.i.d. (twice daily) of TG101209, and samples pooled within the dose groups. Blood mononuclear cells are isolated by a Ficoll cushion centrifugation method (600 RCF and 30 min). The isolated cells are subjected to FACS analysis to determine the percentage of GFP-positive tumor cells (that is, Ba/F3-V617F-GFP cells).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

TG101209936091-14-4TG 101209TG-101209FLT3JAKRETAutophagyApoptosisCluster of differentiation antigen 135CD135Fms like tyrosine kinase 3Janus kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TG101209
Cat. No.:
HY-10410
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email address *

Phone number

 

Department *

Organization name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.